These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7501607)

  • 1. [Homozygote deficiency of thiopurine methyltransferase. A contraindication to the use of azathioprine in kidney transplantation].
    Frappier J; Legendre C; Soria-Royer C; Barbanel C; Kreis H; Beaune P
    Presse Med; 1995 Sep; 24(27):1257-9. PubMed ID: 7501607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.
    Kurzawski M; Dziewanowski K; Gawrońska-Szklarz B; Domański L; Droździk M
    Ther Drug Monit; 2005 Aug; 27(4):435-41. PubMed ID: 16044099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine S-methyltransferase polymorphism in Iranian kidney transplant recipients.
    Aghdaie MH; Azarpira N; Geramizadeh B; Sagheb M; Darai M; Rahsaz M; Malekhoseini SA
    Exp Clin Transplant; 2011 Aug; 9(4):241-6. PubMed ID: 21819368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azathioprine-induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients: a family study.
    Escousse A; Mousson C; Santona L; Zanetta G; Mounier J; Tanter Y; Duperray F; Rifle G; Chevet D
    Transplant Proc; 1995 Apr; 27(2):1739-42. PubMed ID: 7725481
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C).
    Kurzawski M; Dziewanowski K; Ciechanowski K; Droździk M
    Transpl Int; 2005 May; 18(5):623-5. PubMed ID: 15819814
    [No Abstract]   [Full Text] [Related]  

  • 6. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
    Ben Ari Z; Mehta A; Lennard L; Burroughs AK
    J Hepatol; 1995 Sep; 23(3):351-4. PubMed ID: 8551001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation].
    Serre-Debeauvais F; Bayle F; Amirou M; Bechtel Y; Boujet C; Vialtel P; Bessard G
    Presse Med; 1995 Jun; 24(21):987-8. PubMed ID: 7667222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.
    Di Salvo A; Fabiano C; Mannara V; Dimarco M; Orlando A; Affronti M; Macaluso FS; Cottone M
    Dig Liver Dis; 2016 Dec; 48(12):1506-1509. PubMed ID: 27665263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase.
    Perri D; Cole DE; Friedman O; Piliotis E; Mintz S; Adhikari NK
    Eur Respir J; 2007 Nov; 30(5):1014-7. PubMed ID: 17978158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal myelotoxicity after azathioprine treatment.
    Slanar O; Chalupná P; Novotný A; Bortlík M; Krska Z; Lukás M
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):661-5. PubMed ID: 18600523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
    Evans WE; Hon YY; Bomgaars L; Coutre S; Holdsworth M; Janco R; Kalwinsky D; Keller F; Khatib Z; Margolin J; Murray J; Quinn J; Ravindranath Y; Ritchey K; Roberts W; Rogers ZR; Schiff D; Steuber C; Tucci F; Kornegay N; Krynetski EY; Relling MV
    J Clin Oncol; 2001 Apr; 19(8):2293-301. PubMed ID: 11304783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
    Sanderson J; Ansari A; Marinaki T; Duley J
    Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of leukopenia incidents following azathioprine therapy after kidney transplantation.
    Oesterwitz H; Horpacsy G; May G; Mebel M
    Eur Urol; 1978; 4(3):167-70. PubMed ID: 350587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.
    Clunie GP; Lennard L
    Rheumatology (Oxford); 2004 Jan; 43(1):13-8. PubMed ID: 14566029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Azathioprine-associated severe myelosuppression: indication of routine determination of thiopurine S-methyltransferase variant?].
    Ngo S; Sauvetre G; Vittecoq O; Lévesque H; Marie I
    Rev Med Interne; 2011 Jun; 32(6):373-6. PubMed ID: 20970225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
    Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.
    Boonsrirat U; Angsuthum S; Vannaprasaht S; Kongpunvijit J; Hirankarn N; Tassaneeyakul W; Avihingsanon Y
    Lupus; 2008 Feb; 17(2):132-4. PubMed ID: 18250137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.